title: [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
authors.affiliation: Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen Macarena (Sevilla).. eliaromerocarreno@gmail.com.
authors.forename: Elia
authors.initials: E
authors.lastname: Romero Carreño
authors.affiliation: Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen Macarena (Sevilla).. eliaromerocarreno@gmail.com.
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Marcos Rodríguez
authors.affiliation: Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen Macarena (Sevilla).. eliaromerocarreno@gmail.com.
authors.forename: Sara
authors.initials: S
authors.lastname: Santana Martínez
authors.affiliation: Unidad de Gestión Clínica de Oncología Médica, Hospital Universitario Virgen Macarena (Sevilla).. eliaromerocarreno@gmail.com.
authors.forename: Luis
authors.initials: L
authors.lastname: de la Cruz Merino
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000235:genetics*; D000069287:Capecitabine / Q000009:adverse effects* / Q000627:therapeutic use; D018270:Carcinoma, Ductal, Breast / Q000150:complications* / Q000188:drug therapy / Q000235:genetics*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D005260:Female; D006801:Humans; D000077341:Lapatinib; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000069287:Capecitabine; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human